Biohaven (BHVN) EBITDA (2021 - 2026)

Biohaven has disclosed EBITDA across 6 years of filings, most recently posting -$130.6 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$130.6 million, up 41.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$644.9 million (up 27.65% YoY), and the FY2025 annual result was -$745.4 million, up 15.79% from the prior year.
• EBITDA came in at -$130.6 million for Q1 2026 at Biohaven, up from -$142.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$68.9 million in Q3 2022 to a low of -$319.7 million in Q2 2024.
• The 5-year median for EBITDA is -$160.1 million (2024), against an average of -$159.8 million.
• Across the five-year window, EBITDA slumped 319.42% in 2022 and jumped 55.49% in 2023, its largest moves.
• Biohaven's EBITDA stood at -$213.4 million in 2022, then grew by 27.97% to -$153.7 million in 2023, then dropped by 23.56% to -$189.9 million in 2024, then rose by 24.85% to -$142.7 million in 2025, then advanced by 8.52% to -$130.6 million in 2026.
• The last three EBITDA figures came in at -$130.6 million (Q1 2026), -$142.7 million (Q4 2025), and -$173.4 million (Q3 2025), per Business Quant data.